Promising Developments in Cullinan Management’s CLN-978 TCE for Autoimmune Diseases Drive Buy Rating
Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical ...
Cullinan Management (CGEM) Has a New Rating from Wedbush
Cullinan Management (CGEM – Research Report) received a Buy rating and a $36.00 price target from Wedbush analyst Robert Driscoll today. The ...